Blue Cross Laboratories, the owner of the Meftal painkiller brand, has clarified that the adverse reaction the Indian Pharmacopoeia Commission (IPC) has flagged is a rare event. The company claims that the product's constituent, mefenamic acid, can cause adverse reactions, including eosinophilia and systemic symptoms (DRESS) syndrome.